RxDoctor Payments Data

Sarabeth Pavelka

Family · Peoria, AZNPI 1043791577

Payments from drug & device makers

$894in general payments, 2019–2025

Across 31 payments — averaging $28.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$296
  • Boston Scientific$165
  • Amgen$97
  • Boehringer Ingelheim$47
  • AbbVie$46
  • Biohaven Pharmaceuticals, Inc.$41
  • plus $201 from 8 others

What the payments were for

  • Food & beverage$894100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$894 in reported general payments places this provider in the 65th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$10,382
Medicare patients
69
Services billed
148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban31$26,357
OzempicSemaglutide19$25,325
AbrysvoRsv Vacc, Pref A And Pref B/Pf50$14,045
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$9,776
JanuviaSitagliptin Phosphate18$9,390
Arnuity ElliptaFluticasone Furoate17$4,334
ShingrixVaricella-Zoster Ge/As01b/Pf20$3,747
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$3,288
Albuterol Sulfate HfaAlbuterol Sulfate62$2,648
Gabapentin94$2,093
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,320
Levothyroxine Sodium102$1,040
Glipizide16$1,039
Lisinopril129$942
Rosuvastatin Calcium82$941

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$296$25,32519 claims
GSKAnoro Ellipta, Arnuity Ellipta, Shingrix$31$17,85751 claims
AbbVieSynthroid$46$78130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,119 family providers in Arizona.

Other family in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →